In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More individuals is going to be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Segment https://rylangsdrc.ambien-blog.com/38428280/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers